Advertisement
News
Advertisement

Biogen Idec and MAKScientific team up on MS drug candidates

Wed, 03/14/2012 - 12:33pm
Mass High Tech: The Journal of New England Technology

MAKScientific, LLC, a privately held company in Boston focused on the discovery of novel therapeutics modulating cannabinoid pathways, today announced that it has entered into an exclusive option and collaboration agreement with Biogen Idec (NASDAQ: BIIB) to develop and commercialize drug candidates for the treatment of multiple sclerosis (MS) and other neurodegenerative diseases.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading